maratoolCHA2DS2-VASc vs CHADS2
A side-by-side comparison of CHA2DS2-VASc Score and CHADS2 Score.
Both the CHADS2 and CHA2DS2-VASc scores estimate annual stroke risk in non-valvular atrial fibrillation to guide anticoagulation. CHA2DS2-VASc is the refinement of CHADS2 published by Lip et al. in 2010, adding three risk factors (vascular disease, age 65–74, female sex) and reweighting age ≥ 75.
Current guidelines (2024 ACC/AHA, 2024 ESC) recommend CHA2DS2-VASc as the primary risk score because it identifies more "truly low-risk" patients (score = 0) who do not benefit from anticoagulation, and reclassifies many patients previously scored as low risk by CHADS2.
When to use CHA2DS2-VASc Score
Use CHA2DS2-VASc by default for any patient with non-valvular atrial fibrillation. It is the score embedded in current guideline recommendations for anticoagulation decisions. The expanded factors make it more sensitive at identifying low-risk patients (score = 0 in men, 1 in women) who can avoid anticoagulation.
When to use CHADS2 Score
Use CHADS2 only when you need to compare to historical literature or institutional protocols still calibrated on the older score. CHADS2 is faster to compute (5 inputs vs 7) but undertreats patients with vascular disease or female sex when those are the only risk factors.
Side-by-side comparison
| CHA2DS2-VASc | CHADS2 | |
|---|---|---|
| Year published | 2010 (Lip et al.) | 2001 (Gage et al.) |
| Number of inputs | 7 factors | 5 factors |
| Max score | 9 | 6 |
| Adds over predecessor | Vascular disease, age 65–74, female sex | — |
| Age scoring | 65–74 = 1, ≥ 75 = 2 | ≥ 75 = 1 |
| Anticoag threshold (men) | ≥ 2 | ≥ 2 |
| Anticoag threshold (women) | ≥ 3 | ≥ 2 |
| In current guidelines | Primary recommendation (2024 ACC/AHA, ESC) | Largely retired |
| Low-risk detection | Better (more true-zero) | Misses some |
Bottom line
For new clinical decisions, use CHA2DS2-VASc. Reserve CHADS2 for comparison with older literature or audit work.
Frequently asked questions
Should female sex alone justify anticoagulation?
No. A woman with no other risk factors (CHA2DS2-VASc = 1 from sex alone) does not require anticoagulation under current guidelines. The sex factor is only weighted when other risks are also present.
Is CHADS2 still useful?
It is mostly retired for new decisions but remains useful for reading older trials and for institutions still using CHADS2-based dashboards. The faster calculation makes it occasionally convenient for triage.
When does CHA2DS2-VASc reclassify a CHADS2 patient?
Most often when the patient is between 65–74 (gets 1 extra point), has vascular disease (1 point), or is female (1 point only when combined with other risks). These bump previously low-risk CHADS2 patients into anticoagulation territory.
Should I also assess bleeding risk?
Yes — combine CHA2DS2-VASc with HAS-BLED. A high HAS-BLED does not contraindicate anticoagulation but flags modifiable bleeding risks (uncontrolled hypertension, NSAID/alcohol use, labile INR).